COVID-19 Drug Treatment in China
| Autor: | Xinrong Yang, Zhibin Wang, Shuang Jiang, Linzi Fan, Chunjuan Yang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) medicine.disease_cause Biochemistry 03 medical and health sciences Drug treatment 0302 clinical medicine Drug Discovery Genetics medicine Global health China Intensive care medicine Coronavirus Pharmacology SARS-CoV-2 business.industry Hot Topic New drug research and development COVID-19 Outbreak 030104 developmental biology 030220 oncology & carcinogenesis Related research business Medical treatment |
| Zdroj: | Current Pharmacology Reports |
| ISSN: | 2198-641X |
| Popis: | Purpose of Review An unprecedented outbreak of the novel coronavirus in China (COVID-19) occurred in December 2019, and then engulfed the entire world, presenting a significant and urgent threat to global health. Many research institutes have been involved in the development of drugs and vaccines against COVID-19. Recent Findings At present, the strategy of new use of old drugs is mainly used to screen candidate drugs against the novel coronavirus (later termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune response. Related research has made great progress. Summary In this review, we summarize the drugs used for COVID-19 treatment in China based on the emerging basic and clinical data. It is hoped that this review will be useful to provide guidance for the prevention, treatment, and control of COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink